重组人干扰素α-2b注射液联合ALA-PDT疗法对尖锐湿疣患者外周血CD4^+/CD8^+水平及预后的影响

Effects of recombinant human interferon alpha-2b injection combined with 5-aminolevulinic acid photodynamic therapy on the prognosis and CD4^+/CD8^+ levels in peripheral blood of patients with condyloma acuminatum

目的探讨重组人干扰素α-2b注射液联合5-氨基酮戊酸光动力(ALA-PDT)疗法对尖锐湿疣患者外周血CD4^+/CD8^+水平及预后的影响。方法选取2015年2月至2018年2月陕西省地方病防治研究所诊治的265例尖锐湿疣患者为研究对象,采用随机数字表法分将其分为研究组(n=133)与对照组(n=132)。研究组患者在对照组治疗的基础上采取重组人干扰素α-2b注射液治疗,对照组患者采取ALA-PDT疗法治疗,观察比较两组患者疗效、复发率和不良反应发生率,比较治疗前后两组患者血清肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)水平和T淋巴细胞(CD4^+、CD8^+、CD4^+/CD8^+)水平。结果(1)疗效:研究组患者总有效率(92.5%)高于对照组患者(82.6%),其差异具有统计学意义(P<0.05);(2)免疫功能:研究组患者治疗后血清CD4^+、CD4^+/CD8^+水平高于对照组患者,血清CD8^+水平低于对照组患者,其差异均具有统计学意义(均P<0.05);(3)炎性因子水平:研究组患者治疗后血清TNF-α水平低于对照组患者,血清IL-6水平高于对照组患者,其差异均具有统计学意义(均P<0.05);(4)预后:研究组患者复发率(0.8%)低于对照组患者(9.8%),其差异具有统计学意义(P<0.05);(5)安全性:研究组患者不良反应总发生率(6.0%)高于对照组患者(3.0%),其差异无统计学意义(P>0.05)。结论尖锐湿疣患者采取重组人干扰素α-2b注射液联合ALA-PDT疗法,治疗效果确切,能够改善其免疫功能和炎性因子水平,降低复发率,且具有安全性。

Objective To explore the effect of recombinant human interferon alpha-2 b injection joint with 5-aminolevulinic acid photodynamic therapy(ALA-PDT) on the prognosis and CD4^+/CD8^+ levels in peripheral blood of patients with condyloma acuminatum(CA). Methods 265 patients with CA in Shaanxi Provincial Institute of Endemic Disease Control from February 2015 to February 2018 were randomly divided into control group(n=132) and research group(n=133). The control group was treated with ALA-PDT therapy and the research group was treated with recombinant human interferon alpha-2 b injection on the basis of the control group. The curative effect, recurrence rate and incidence of adverse reactions were observed and compared between the two groups. Levels of tumor necrosis factor-alpha(TNF-alpha), interleukin-6(IL-6) and T lymphocyte(CD4^+, CD8^+, CD4^+/CD8^+) were measured. Results ① The total effective rate of the research group(92.5%) was higher than that of the control group(82.6%), with statistically significant difference(P<0.05).② After treatment, the levels of serum CD4^+, CD4^+/CD8^+ in the research group were higher than those of the control group, and the levels of serum CD8+ were lower than those of the control group, with statistically significant differences(all P<0.05).③ The levels of serum TNF-alpha in the research group were lower than those of control group, and the levels of serum IL-6 were higher than those of the control group, with statistically significant differences(all P<0.05)④ The recurrence rate in the research group(0.8%) was lower than that in the control group(9.8%), with statistically significant difference(P<0.05).⑤ The total incidence of adverse reactions in the study group(6.0%) was higher than that in the control group(3.0%), without statistically significant difference(P>0.05). Conclusions Recombinant human interferon alpha-2 b injection joint with ALA-PDT is effective and safe in the treatment of patients with CA, which can improve the immune function and the level of inflammatory factors and reduce the recurrence rate.